X63da1fd8.ca5b.494f.8625.4daf5f898f53
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.490
- TNFA_SIGNALING_VIA_NFKB+0.430
- E2F_TARGETS+0.380
- IL6_JAK_STAT3_SIGNALING+0.370
- INFLAMMATORY_RESPONSE+0.360
- G2M_CHECKPOINT+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.320
- INTERFERON_GAMMA_RESPONSE+0.310
- MYC_TARGETS_V1+0.300
- ANGIOGENESIS+0.240
Top 10 suppressed
- ADIPOGENESIS-0.290
- FATTY_ACID_METABOLISM-0.290
- XENOBIOTIC_METABOLISM-0.290
- ESTROGEN_RESPONSE_EARLY-0.280
- ESTROGEN_RESPONSE_LATE-0.250
- KRAS_SIGNALING_DN-0.250
- NOTCH_SIGNALING-0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- BILE_ACID_METABOLISM-0.230
- CHOLESTEROL_HOMEOSTASIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-91-6848-01A-11R-1949-07 | — | cohortA1 | 0.822 |
| 2 | SRR493951 | — | cohortMD2 | 0.804 |
| 3 | TCGA-CQ-A4CB-01A-11R-A24Z-07 | — | — | 0.779 |
| 4 | TCGA-E2-A1AZ-01A-11R-A12P-07 | — | D | 0.777 |
| 5 | C3N-03063 | — | cohortA1 | 0.777 |
| 6 | SRR934732 | — | — | 0.776 |
| 7 | SRR8518180 | — | D | 0.776 |
| 8 | TCGA-DK-A3WX-01A-22R-A22U-07 | — | — | 0.769 |
| 9 | TCGA-83-5908-01A-21R-2287-07 | — | cohortA1 | 0.769 |
| 10 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.140 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |